PCRX
Pacira BioSciences
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: PCRX
- PE Ratio
As of Jun 3, 2026, the Pacira BioSciences stock's PE ratio is 186.0. This results from the current EPS of $0.12 and stock price of $22.32.
PCRX PE ratio history
The PE ratio of Pacira BioSciences has averaged 124.54 over the last eight years. The current PE ratio of 186.0 is 49% above the historical average. Over the past eight years, PCRX's PE ratio was at its highest in the Sep 2019 quarter at 761.4, when the stock price was $38.07 and the EPS was $0.05. The lowest value was in the Jun 2021 quarter, when it reached 15.09 with a price of $60.68 and an EPS of $4.02.
Pacira BioSciences PE ratio by year
Maximum annual increase: 260.91% in 2021
Maximum annual decrease: -66.39% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 161.75 | N/A | $25.88 | $0.16 |
| 2024 | N/A | N/A | $18.84 | -$2.15 |
| 2023 | 37.08 | -66.39% | $33.74 | $0.91 |
| 2022 | 110.31 | 74.16% | $38.61 | $0.35 |
| 2021 | 63.34 | 260.91% | $60.17 | $0.95 |
| 2020 | 17.55 | N/A | $59.84 | $3.41 |
| 2019 | N/A | N/A | $45.3 | -$0.27 |
| 2018 | N/A | N/A | $43.02 | -$0.01 |
| 2017 | N/A | N/A | $45.65 | -$1.07 |
| 2016 | N/A | N/A | $32.3 | -$1.02 |
| 2015 | 1,535.8 | N/A | $76.79 | $0.05 |
| 2014 | N/A | N/A | $88.66 | -$0.39 |
| 2013 | N/A | N/A | $57.49 | -$1.93 |
| 2012 | N/A | N/A | $17.47 | -$1.72 |
| 2011 | N/A | N/A | $8.65 | -$2.64 |
Pacira BioSciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 188.33 | 16.43% | $22.6 | $0.12 |
| Dec 2025 | 161.75 | 188.74% | $25.88 | $0.16 |
| Sep 2025 | 56.02 | N/A | $25.77 | $0.46 |
| Jun 2025 | N/A | N/A | $23.9 | -$2.77 |
| Mar 2025 | N/A | N/A | $24.85 | -$2.25 |
| Dec 2024 | N/A | N/A | $18.84 | -$2.15 |
| Sep 2024 | N/A | N/A | $15.05 | -$1.97 |
| Jun 2024 | 20.88 | 8.64% | $28.61 | $1.37 |
| Mar 2024 | 19.22 | -48.17% | $29.22 | $1.52 |
| Dec 2023 | 37.08 | -83.08% | $33.74 | $0.91 |
| Sep 2023 | 219.14 | N/A | $30.68 | $0.14 |
| Jun 2023 | N/A | N/A | $40.07 | -$0.11 |
| Mar 2023 | N/A | N/A | $40.81 | -$0.23 |
| Dec 2022 | 110.31 | -6.68% | $38.61 | $0.35 |
| Sep 2022 | 118.2 | 76.39% | $53.19 | $0.45 |
PCRX Price vs fair value
PCRX average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
PCRX's current P/E ratio is above the 3, 5 and 10-year historical averages.
PE comparison
Pacira BioSciences's P/E of 186 is above the Healthcare sector and the industry average.
PCRX PE vs peers
Compared to its peer stock OMER, PCRX's PE ratio stands higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| OMER Omeros Corp | 7.88 | $741.12M |
| PCRX Pacira BioSciences Inc | 188.92 | $892.02M |
| HRTX Heron Therapeutics Inc | N/A | $90.36M |
| CPIX Cumberland Pharmaceuticals Inc | N/A | $88.55M |
| TVRD Tvardi Therapeutics Inc. | N/A | $28.99M |
Frequently asked questions
What is Pacira BioSciences's PE ratio?
The price to earnings ratio for PCRX stock is 186 as of Jun 3, 2026.
What is the 3-year average PE ratio for Pacira BioSciences (PCRX)?
The 3-year average PE ratio for PCRX stock is 100.35.
What is the 5-year average PE ratio for Pacira BioSciences (PCRX)?
The 5-year average PE ratio for PCRX stock is 86.1.
What is the highest PE ratio for PCRX?
The highest quarterly PE ratio in the last eight years has been 761.4 and it was in the Sep 2019 quarter.
How does the current PE ratio for PCRX compare to its historical average?
PCRX's price to earnings ratio is currently 49% above its 8-year historical average.
Why is Pacira BioSciences's PE ratio so high?
PCRX's PE ratio of 186 is considered high because the company's stock price is trading at a higher multiple of earnings.
How is PCRX's PE ratio calculated (Pacira BioSciences PE ratio formula)?
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jun 3, 2026), Pacira BioSciences's stock price is $22.32. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.12. Therefore, Pacira BioSciences's P/E ratio for today is 186. PE RATIO(186) = STOCK PRICE($22.32) / TTM EPS($0.12)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.